Latest News
BiomimX interviews
Playlist
2024
WORD+
February 11-13
🎉 Thank you to everyone who visited BiomimX® Srl booth at WORD+ 2025 WORC.Community !
A big thanks also to the organizers, speakers, and partners for making WORD+ 2025 a success!
It was inspiring to connect with so many brilliant minds in the Organoid and Organ-on-Chip community. We had fantastic discussions about our Beating Organs-on-Chip technology and how we are transforming preclinical research and boosting pharmaceutical pipelines.
🌟 Looking forward to future collaborations and more breakthroughs in the field.
💡 Stay tuned for more updates from BiomimX!
Kick-off meeting PHOENIX
February 3-5
Cooperation, sharing and synergy, three key-words that marked the beginning of PHOENIX project, funded under the Horizon Europe programme (HORIZON-HLTH-2024-TOOL-05-two-stage) and coordinated by Prof. Marco Rasponi from the Department of Electronics Information and Bioengineering of Politecnico di Milano.
PHOENIX aims to revolutionize biomedical research by developing advanced Organs-on-Chip (OoC) platforms that will foster the investigation of complex pathologies, focusing on cardiac and neuro-muscular diseases. Such platforms will enhance our understanding of disease mechanisms, accelerating drug discovery and ultimately leading to reduced animal testing.
On February 3-4, 2025, the kick-off meeting brought together the partners of the project, nine organizations coming from various parts of Europe, each of them bringing diverse background and expertise to the table.
Milestones were set, the roadmap was outlined, now the project is ready to start. Stay tuned!
BioFit
December 2-5
As a novel member of MabDesign, BiomimX® Srl this year attended Biofit in Lille, France.
Our CEO, Dr. Paola Occhetta and our Commercial Science Leader, Dr. Erika Ferrari represented the company! In addition, our CEO and Co-founder, Dr Paola Occhetta, delivered her pitch on December 4th.
Queen Mary University of London Facilities
We are incredibly proud to announce that Queen Mary University of London recently acquired different in vitro model facilities for educational purposes and BiomimX uBeat® setup, is one of them!
These facilities have been funded through a mixture of commercial partnerships, internal funding, research project grants and a large infrastructure grant from the NC3Rs and BBSRC. The facilities are integrated with category II cell culture, advanced microscopy and molecular biology and biochemistry facilities.
Find out more about our uBeat® Setup at Queen Mary University of London at the following link: https://www.cpm.qmul.ac.uk/facilities/biomimx/
Open Job Position
Junior Product Specialist
📣 We are looking for a Junior Product Specialist to join our team! 📣
If you have a background in biomedical sciences and a strong interest in commercial activities, pharmacology, and organs-on-chip technology, and enjoy working in a dynamic, interdisciplinary environment, we would love to connect with you!
Send your resume and cover letter to the attention of Dr. Erika Ferrari at careers@biomimx.com
Innovation Radar Prize
November 11
🎉 Exciting News: BiomimX is a Finalist for the Innovation Radar Prize 2024! 🎉
BiomimX has been selected as a finalist in the Health Tech category of the prestigious Innovation Radar Prize 2024!
Join us for the grand presentation at The Europas Awards on the afternoon of November 11th at La Distillerie in Lisbon! 🏆 Every finalist will deliver a 3-minute pitch, and we are proud to be represented by our co-founders, CEO Paola Occhetta and CTO Marco Rasponi. Our CEO will take the stage to deliver BiomimX’s 3-minute pitch!
Follow this link to register for the awards presentation: https://lu.ma/europas100
CPHI
October 8-10
🎉 Thank You for visiting BiomimX® Srl #Booth at CPHI 2024! 🎉
We had an incredible time at CPHI 2024, and we want to extend a huge thank you to everyone who stopped by our startup booth and to the organization of the event, Valentina Mognoni!
It was amazing to share our journey and showcase our organ-on-chip technology in one of the greatest events in the field of pharmaceutical industries. We were also pleasantly surprised to see so many innovative start-ups represented alongside us!
🌟 Looking forward to future collaborations and more breakthroughs in the field.
Paper Publication in Collaboration with Synartro
September 24
BiomimX is excited to announce that the results of our collaboration with Synartro have just been published on Advanced Healthcare Materials: https://doi.org/10.1002/adhm.202401187
The collaboration was born from the need to test the efficacy of SYN321, a pioneering Intra-Articular (IA) drug candidate for Osteoarthritis (OA) therapy, on an in vitro model able to recapitulate the key pathological features of OA. We brought our technological and biological expertise into this collaboration by testing the effect of SYN321 on our model of OA, developed in a novel platform, the uBeat® MultiCompress, tailored for the injection of viscous therapeutics.
The findings of this research, have also been accepted by Swedish regulatory authorities as part of an Investigational New Drug (IND) application, clearing the way for phases 1 and 2a of clinical trials.
Thanks to all collaborators and authors of this paper: Cecilia Palma, Stefano Piazza, Roberta Visone, Rune Ringom, Ulf Björklund, Antonio Bermejo Gómez, Marco Rasponi, Paola Occhetta
Eurotox
September 8 - 11
We are proud of Caterina Pernici for winning the Gerhard-Zbinden Early Career Award Best Poster Presentation for drug-oriented toxicological research at EUROTOX Congress!
Her research represents a breakpoint in the field of cardiotoxicity. She performed a study over 19 known compounds in our Heart-on-Chip model (uHeart), validating its reliability in assessing drug-induced contractility alterations and in predicting cardiotoxicity.
🎉 Congratulations to Caterina!! 🎉
SLAS Microscale Innovation in Life Sciences Symposium
September 11 - 12
📢 Our Co-founders Prof. Paola Occhetta and Prof. Marco Rasponi will be in Cambridge, UK on 11-12 September for the SLAS (Society for Laboratory Automation and Screening) Symposium on Microscale Innovation in Life Sciences.
Our CEO Paola Occhetta will be presenting a Poster: “In Situ Monitoring of Drug Induced QT Alterations and Pro-arrhythmic Effects of Compounds Within a 3D Beating Heart-on-Chip Platform”. Go check her poster presentation if you are interested in our Heart-on-Chip model (uHeart) that will revolutionize in vitro toxicology.
Don’t miss this opportunity to meet our Co-founders and Key Opinion Leaders in the field of Organs-on-Chip!
Eurotox
September 8 - 11
📢 Next week our R&D Product Engineer Caterina Pernici will be in Copenhagen for the Annual EUROTOX Congress!
She will present a poster on the prediction of drug-induced cardiac contractility alterations in uHeart, our model of 3D beating cardiac tissue in vitro. uHeart is indeed able to detect drug-induced arrhythmic events and to predict compounds cardiotoxicity with 92% accuracy and 100% specificity.
If you’re interested in learning more about her research results, don’t miss the poster presentation!
Team Building 2024
July 23
Team Building!!!
Our team had an incredibly special #TeamBuilding experience by diving into Oriental cuisine! 🍜🍲
We worked together to prepare delicious dishes like Pad Thai and Pork served with a coconut milk sauce. It was an extraordinary opportunity to strengthen teamwork and learn new culinary skills. We brought our precision form the lab to the kitchen with a refined use of knives 🔪. The Matcha pudding team distinguished themselves with exceptional execution and elegant presentation!
And yes, we can now officially add “Master Chefs” to our resumes!
EUROoCS
July 3 - 5
🎉 This year, the EUROoCS annual meeting was particularly special for us since it was hosted and organised by Politecnico di Milano, and our Co-founders and Professors @ POLIMI Paola Occhetta and Marco Rasponi were Co-chairs of the conference!!
BiomimX was an exhibitor and our team members presented their outstanding work with 4 different posters:
- Caterina Pernici: “Development of a tool to elucidate the clinical phenotype of patients affected by genetic cardiomyopathy in a 3D beating heart-on-chip platform”
- Elena Vatrano: “On-chip tracking of human mesenchymal cells gene expression profile to unravel mechanically driven chondrogenesis processes”
- Marco Mondini: “Development and characterization of mechanical-stimulated atrial and ventricular 3D heart-on-chip models scheduled during the lunch break”
- Erika Ferrari: “Assessing the feasibility of innovative Liver-on-Chip models for in vitro hepatotoxicity screening”
ECM 2024
June 17-19
📢 BiomimX was one of the exhibitors at the the Extracellular Matrix Pharmacology Congress (ECM) in Copenhagen, Denmark, this year!
Our CEO, Dr. Paola Occhetta, took the stage for an oral presentation on the pathological hallmarks of cardiac fibrosis in a OoC for predicting drug efficacy. Also, Erika Ferrari and Stefano Piazza presented their posters.
MPS World Summit
June 10 - 14
📢 Our co-founders, Dr. Paola Occhetta & Dr. Marco Rasponi, have been in Seattle for the MPS World Summit!
Paola Occhetta, CEO, had a presentation on how our beating heart-on-chip can elucidate the clinical phenotype of patients affected by genetic cardiomyopathies.
ESTIV 2024
June 3 - 6
🌍 BiomimX was an exhibitor at European Society of Toxicology in Vitro (ESTIV) International Congress in Prague this year!
🎉 Congratulations to our Junior R&D Product Engineer Caterina Pernici for winning the Best Poster Award!! 🎉
Also, Erika Ferrari won the Travel Grant and Caterina Pernici received the EUROTOX Toxicology Societies Travel Grant!
A big thank you to the organization of the Congress and to all the attendees for this memorable event!
Hosted Seminar - IBEC, Barcelona
May 17
🌐 Our Commercial Science Leader Erika Ferrari and our Lead Marketing Assistant Micol D’Antonio were invited at the Institute for Bioengineering of Catalonia (IBEC) in Barcelona to present the uBeat® Technology and do a demonstration in a research lab within the Institute.
They also had the opportunity to meet researchers from the Faculty of Pharmacy of the Universitat de Barcelona.
Warm thanks to the coordinators of the Seminar, Cristina Arimany Nardi and Agostino Romeo, and to all attendees and researchers we met!
OARSI 2024
📢 Exciting news! Next week, BiomimX® Srl will be attending the OARSI World Congress on Osteoarthritis 2024!
Join us to learn more about our Joint on Chip – uKnee – and its applications for osteoarthritis (OA) modelling in vitro and OA therapy studies. Don’t miss the Oral presentation by our CEO, Dr. Paola Occhetta, during the “Joint Related Tissue” session (Room 2, Messe Wien Exhibition & Congress Center, Vienna, Austria).
We are thrilled to announce that BiomimX will also be exhibiting at OARSI for the first time! Visit us at Booth#15 on April 18-21 to discover more about our company and explore our Beating Organs on Chip
🌐 Looking forward to meeting you in Wien!
Workshop - Proprietà Intellettuale & Biotechnology April 10, 17.00 - 18-00
The online workshop “Proprietà Intellettuale & Biotechnology” will be held on April 10, from 5pm to 6pm. The workshop is organized by IP4Growth, and will host Dorotea Rigamonti from MARCHI & PARTNERS S.R.L., e Paola Occhetta, CEO and co-founder of BiomimX® Srl.
💡BiomimX® Srl, introduced an innovative technology that allows the drug screening on in vitro human models, providing a valid alternative to animal testing. Marchi & Partners is the consultancy firm that supported BiomimX in the release of one of its patents.
Society of Toxicology 2024
In 2 weeks BiomimX® Srl will be attending the Society of Toxicology (SOT) 2024!
Want to know more about our Beating Organs on Chip and their application in toxicology?
Come to Booth #735 open on March 11th-13th (Salt Palace Convention Center, Salt Lake City, Utah 🇺🇸 ) and don’t miss 2 Poster Presentations by our Commercial Science Leader Dr. Erika Ferrari and our R&D Product Engineer Caterina Pernici.
(P269) “Advancing Drug Safety Assessment: A Compartmentalized Multiorgan-on-Chip Platform to Study Off Target Cardiotoxicity of Liver-Metabolized Anticancer Drugs” – Erika Ferrari, 8:30 – 11:30 am, 14th March, Salt Palace Convention Center, Hall E.
(P176) “Qualification of a 3D Beating Heart-on-Chip Platform as a Preclinical Tool to Predict Human Cardiac QT Alterations and Pro-Arrhythmic Effects of Compounds” – Caterina Pernici, 8:30 – 11:30 am, 14th March, Salt Palace Convention Center, Hall E.
Multistakeholder Kick-off Workshop
Yesterday, our CEO Paola Occhetta participated in the Multistakeholder Kick-off Workshop organized by Sonja Beken of the European Medicines Agency 3Rs Working Party.
Scientific and regulatory discussions were conducted regarding the qualification of MicroPhysiological Systems (MPS), including Organ-on-Chip (OoC) models, for specific contexts of use in the pharmaceutical area.
Paola Occhetta provided a detailed overview of our uHeart model as a preclinical tool for safety pharmacology testing.
The workshop was fascinating, uniting #MPS developers, regulatory bodies, and preclinical adopters with the aim of defining a common path towards qualification of new in vitro methods (including #OoC) to be adopted in the drug discovery and development process.
We appreciate the invitation and the consideration of BiomimX® Srl as a potential key player in this field.
Let’s continue to pursue this goal.
2023
Happy Holidays from BiomimX Team!
We are almost at the end of 2023 and time has come to disconnect from the routine, relax and take a look at this past year, that brought us both new #challenges and very happy moments.
This wouldn’t have been possible without the effort and the contribution of each member of our fantastic #Team!
🎯Our scientific results and technical solutions were presented in 11 scientific events (e.g., MPS/EUROoCS, ESTIV-ASCCT, SPS where a Junior Travel Award was assigned to our Junior R&D Product Engineer Caterina Pernici)
🎯We took part in 4 business events (e.g., BIO EUROPE, BIO International Convention, Health Tech Summit)
🎯3 projects eventually evolved in publications:
➡️ LivHeart: A Multi Organ-on-Chip
➡️ 3D human cardiac fibrosis
➡️ 3D human liver-on-chip
🎯Welcome to our new #Team members! We’re thrilled to have PhD Erika Ferrari as our Commercial Science Leader and Marco Mondini as our Junior R&D Scientist
🎯Celebrating a special addition to our #Family! Congratulations to our COO Roberta Visone on the arrival of baby Giovanni
🎯We were granted by the European Commission a Horizon Europe MSCA-DC project ‘MIRACLE’ to deepen our R&D in cardiac pathologies
🎯We started discussing with the European Medicine Agency for the qualification of our #uHeart model for Safety Pharmacology
🎯Scott Woodward started to collaborate with us as Business Advisor
🎯Our President Marco Rasponi was elected Vice-Chair of EUROoCS
Thank you for following us, we’re eagerly anticipating the opportunities and developments that 2024 will bring. Stay tuned for exciting updates!
We wish everyone Happy Holidays and a prosperous New Year!
Are you interested in cardiac fibrosis? Check out our latest publication!
Our COO Dr. Roberta Visone, Dr. Camilla Paoletti et al. present uScar, a 3D organ-on-chip in vitro model of human cardiac fibrosis with physiological beating, generated through mechanical stimulation. This model has been employed for drug screening campaigns (e.g., Pirfenidone and Tranilast) and advanced therapeutics, including miRNA therapy.
The project was carried out in collaboration with Politecnico di Torino and Politecnico di Milano.
SPS Annual Meeting Sept 18-21, 2023
Few days left until the SPS Annual Meeting 2023!
Want to know more about our platforms and their application in cardiotoxicity assessment, don’t miss:
1 Oral Communication by our R&D Product Engineer Caterina Pernici.
“Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform” – Caterina Pernici, 1:30 – 1:45 p.m., 19th September, Silver Hall.
2 Poster Presentations by our Business Developer Erika Ferrari and our R&D Product Engineer Caterina Pernici.
“Investigating in Vitro Off-Target Cardiotoxicity of Liver-Metabolized Anticancer Drugs Through a Multiorgan-on Chip Platform” – Erika Ferrari, 9:30 – 10:00 and 3:00 – 3:30 p.m. 19th September, 2:30 – 3:00 p.m. 20th September, Grand Hall.
“Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform” – Caterina Pernici, 2:30 – 3:00 p.m. 19th September, 9:30 – 10:00 and 3:00 – 3:30 p.m. 20th September, Grand Hall.
Meet us at Booth #607, BiomimX’s Team is ready to welcome you!
MPS World Summit 2023
June 25-30
Such a great time!
One intense and fruitful week in Berlin at MPS World Summit and EUROoCS, meeting old friends and creating new synergies for BiomimX!
This event gave us the opportunity to connect with the scientific community and gain insights about the latest scientific results, making all of us feel part of a remarkable process, shaping together the future of medicine through microphysiological systems.
Congratulations to our R&D Product Engineer Stefano Piazza, our Business Developer Erika Ferrari and our R&D Engineer Ferran Lozano who presented the results of their work involving the application of our Organ-on-Chip platforms for physio-pathological modelling and drug screening.
Special thanks to Stefano Piazza and Erika Ferrari, who led an educational workshop illustrating to the participants our commercially available products and how to use them in the lab.
See you all next year in Milan for the next EUROoCs chapter and in Seattle for the next MPS Summit!
SIOoC in Rome – May 4-5, 2023
Our collaborators Alessandro Cordiale, Giacomo Cretti and Elisa Monti, PhD candidates at MiMic Lab of Politecnico di Milano, are taking part in the first congress of Società Italiana Organ-on-Chip, happening in Rome on May 4th-5th.
Don’t miss their talks if you want to know more about how our uBeat® technology is used in research.
📢 Next week our R&D Engineer Ferran Lozano is taking part in Termis Americas Annual Meeting, happening in Boston, US.
Don’t miss his poster to discover our #uHeart model and its application in drug screening tests.
“Cardiotoxicity Study On A 3D Heart-on-Chip Platform By Evaluating The Effect Of Compounds On The QT Alterations And The Pro-Arrhythmic Response”, 5:15 PM – 7:15 PM, Poster Session 3, Thursday, April 13, 2023.
MPS Educational Workshop
On the occasion of the MPS World Summit, BiomimX is taking part in the Educational Workshops together with other companies operating in the field of Organ-on-Chip (OOC) and Microphysiological systems (MPS).
Don’t miss the chance to attend a hands-on demo of commercially available technologies!
OoC Master Class 2023
On July 18th and 19th BiomimX is taking part in the OoCMasterClass, Nijmegen, the Netherlands, jointly organized by Radboudumc Stem Cells Technology Center and AZAR Innovations.
🗓️ Registrations are open and end in April 30th, save the date!
ESTIV – American Society
Our Business Developer PhD Erika Ferrari was invited to the ESTIV-American Society for Cellular and Computational Toxicology Webinar. Erika is going to present a MultiOrganonChip platform which integrates liver and cardiac models for drug safety testing and which she developed at Politecnico di Milano during her PhD.
📢@OARSI World Congress on Osteoarthritis is happening this week in Denver, Colorado!
Our collaborator @Cecilia Palma, PhD candidate at MiMic Lab of @Politecnico di Milano, is taking part in the congress and she is presenting the results of her work on an osteoarthritis-on-chip model, exploited to test a novel drug candidate developed by our partner @Synartro.
“Efficacy assessment of the novel combined anti-OA treatment SYN321 in an advanced mechanically active osteoarthritis-on-chip model”, 4.15 – 5.00 p.m., Poster Session, Saturday March 18 and Sunday March 19.
Don’t miss her poster if you want to discover our #uKnee OA model and its application in drug efficacy assessment.
📢 New upcoming event!
We are happy to announce that BiomimX is sponsor at the first congress of Società Italiana Organ-on-Chip, taking place on May 4-5 in Rome. Don’t miss the opportunity to learn more about the Italian roadmap for Organs-on-Chips.
🗓️ Abstract submission is open and ends in March 15, save the date!
BIO-EUROPE SPRING, March 20-22, 2023
Save the date!
We are glad to share that BiomimX® is going to participate to Bio-Europe Spring 2023.
OARSI, March 10-17,2023
Save the date!
We are glad to share that BiomimX® is going to participate to OARSI World Congress on Osteoarthritis.
January 16
What a great way to start 2023! Our team is growing: Erika Ferrari, PhD joined BiomimX as Junior Business Developer. Check the team page to get to know her better.
Welcome on board Erika!
2022
Thank you for following us, we are excited for 2023 to come, stay tuned!
For now, we wish everyone Happy Holidays and a prosperous New Year!
BiomimX Team
MPS world Summit
🗓️ Save the date!
The Microphysiological Systems World Summit is happening in Berlin, from June 26th to June 30th, 2023.
📢 Abstract submission is open, don’t miss the chance!
BIOFIT 2022
Save the date!
On November 29th and 30th BiomimX® Srl is taking part in #BioFIT2022, the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovations in the field of Life Sciences.
Don’t miss the opportunity to meet our CEO Paola Occhetta and CTO Marco Rasponi to discover BiomimX® Srl and its solutions!
We still have few available slot, book your meeting with us today!
Italian Chapter Launch / Nucleate IT – November 26
Many thanks to Nucleate IT for inviting us to the launch of their Italian Chapter!
During the event, we’ll have the opportunity to participate to a pitch competition together with other five biotech companies.
ESTIV November 21-25
Next week our COO Roberta Visone and our collaborator Erika Ferrari, PhD student at MiMic Lab of Politecnico di Milano, are taking part in #ESTIV2022, the International Congress of the European Society of Toxicology in Vitro ESTIV, happening in Barcelona, Spain, from 21st to 25th November 2022.
Don’t miss their talks if you want to know more about our #uHeart cardiac model and its interaction with other organs!
#AIXASummit, November 17
Today our CEO Paola Occhetta took part to the fifth edition of #AIXASummit, the annual exhibition of #artificialintelligence applications for business.
Special thanks to Marco Venturelli, Ambassador at Federated Innovation Network @MIND Milano Innovation District, who invited us to share BiomimX® Srl‘s vision on the future of the health sector through artificial intelligence. The combination of our Organs-on-Chip technology with the potentialities of AI will allow us to change the approach to healthcare and take another step towards #precisionmedicine.
2022 Italian Organ-On-Chip Industry workshop
BiomimX, React4Life and IVTech partnered and organized the very first Italian Organ-On-Chip workshop. The event, held in Genoa, gathered experts in the field that gave their personal perspective on how the emerging Organ-On-Chip technologies are contributing to boost biomedical research.
Download the official Press Release to know more about the event and the three companies that organized it.
Demo Day of Berkeley SkyDeck Europe, Milan
Here we are! After six intense months of work and preparation, the Demo Day of Berkeley SkyDeck Europe, Milan, has arrived!
We are extremely proud to announce that BiomimX is one of the nine startups selected for the first ever batch of Berkeley SkyDeck Europe, Milan.
The acceleration program Berkeley SkyDeck Europe, Milan was launched in December by Berkeley SkyDeck, Cariplo Factory, Lendlease – with the contribution of Regione Lombardia and Fondazione Cariplo.
It has been an inspiring journey, powered by amazing people (among many others George Panagiotakopoulos Andrea Ruckstuhl Alberto Sangiovanni-Vincentelli Argia Galliano Andrea Censoni Andrea Beretta Andrea Magrini Enrico Noseda Caroline Winnett) and enforced by priceless advisors Scott Woodward and Marita Cavalcanti, which help us to bring our business to the next level.
In BiomimX we have a clear mission: Advance the discovery of new therapies for complex diseases, by staying human. Curious to know more? Don’t hesitate to contact us: info@biomimx.com
Modernization Act 2.0
📢 Good news! On Sept 29th, the US Senate passed the #FDA #ModernizationAct2.0, which represents a huge step forward for all those involved in drug development.
The Bill empowers the use of cutting-edge testing methods, such as #OrgansOnChip, for evaluating drugs safety and effectiveness.
💡An unprecedented opportunity for reducing animal testing and unlocking the potential of such technologies!
2022 Italian Organ-On-Chip Industry workshop
New upcoming event!
We are glad to announce the first Italian Industry Workshop that is taking place in Genoa on October 24 with React4life and IVTech.
Ivan Martin and Lena Smirnova together with other great experts in this filed are going to give a wide overview of how Organ-On-Chip applications are furthering the biomedical research.
Notably, Luigi Nezi from IEO Istituto Europeo di Oncologia is going to illustrate how BiomimX® Srl products supported his work.
You’ll also have the opportunity to attend a hands-on demo of commercially available #organonchip technologies.
Don’t miss this occasion!
To register to the event please write an email to ItalianOOC@gmail.com
2ND WORKSHOP ON NEXT GEN ORGAN-ON-CHIP & ORGANOIDS – Geneva, August 23-24
We are happy to announce that BiomimX is going to be one of the exhibitors in the 2nd networking workshop on Next Gen Organ-On-Chip & Organoids to be held on August 23-24 in Geneva.
Also, our CEO, Paola Occhetta is going to present “Beating organs-on-chip for human organs and diseases modeling: advanced preclinical tools for screening drugs and medical devices” on August 23 at 2PM.
Come to our booth and take the opportunity to discover how our Beating Organs-on-Chip will reshape the future of drug discovery!
EUROOCS 2022 – Grenoble, July 4-5
BiomimX is silver sponsor at #EUROoCS Annual meeting. We believe that Organs on Chip will change the future and for this reason we are happy to support our European Organs on Chip Society. Meet us in Grenoble to learn more about our Beating Organs on Chip solutions.
BIO 2022 – San Diego, June 13-16, 2022
We are thrilled to announced that the European Commission choose BiomimX among the 20 EU SMEs that will represent Europe during the BIO 2022 in San Diego! We are looking forward for an exciting exhibition week at the European Pavillon! Stay posted, more news will come!
May 30 – June 3, 2022
Do you want to know more about BiomimX’s latest scientific advancement in developing human microphysiological systems? Join us in New Orleans at the MPS World Summit and learn directly from our Team about uKnee, uHeart and uScar models!
May 6, 2022 – ECTS
Save the date! Our collaborator OncoBone Ventures Limited is participating to the European Calcified Tissue Society Conference in Helsinki from May 6 to May 10, 2022. Don’t miss the chance to be updated on our uKnee model, presented by Tiina Kähkönen during the pre-congress session “Osteoarthritis and Bone” on May 6.
While also the startups that won the second edition of Cross The Bridge are taking the next steps in their projects, in this article StartupItalia recalls the four winners of the very first edition, including BiomimX.
We’re happy we took this opportunity !
4th Webinar on Wednesday, April 27, at 4 pm (GMT+2)
In this webinar our COO Roberta Visone is presenting uScar, a model of cardiac fibrosis developed by exploiting BiomimX® uStretch platforms and used in collaboration with Prof. Valeria Chiono from Politecnico di Torino to test advanced cardiac reprogramming therapeutics.
CEN-CENELEC Focus Group on Organ on Chip
On March 2nd, 2022 we participated to the Standards for Organ-on-Chip Focus Group Kick-off Meeting. We are excited to give our contribution in drafting standards in OoC!
The Focus Group shall ensure interaction between all relevant European stakeholders interested in potential standardization in the field of OoC. The Focus Group has been established by European standards organizations CEN and CENELEC with a secretariat by the Dutch organization for standards, NEN
We’re proud to be part of the The North American 3Rs Collaborative (NA3RsC) Microphysiological Systems (MPS) initiative.
The MPS initiative works together to increase industry adoption and regulatory acceptance of MPS technologies with the ultimate goal of refining, reducing, and replacing research animals.
Award
We are happy to share that our CEO, Paola Occhetta, has been selected among the 50 female entrepreneurs supported by the first call of the WomenTech EU program! Stay tuned to know how this exciting program will help us accelerating our vision!
We are glad to share our recently published review on Biophysical Reviews: “Current strategies of mechanical stimulation for maturation of cardiac microtissues”.
March 11, 2022
We are participating to CellToxDays 2022! Paola Occhetta, CEO of BiomimX, is presenting “Beating Organs-on-Chip: from single functional tissues to multiorgan models” on March 11th, at 10.40 AM (CET).
2021
December 7, 2021
Biofit 2021 is coming in few weeks, and we are ready!
Paola Occhetta is presenting BiomimX® Srl during the Startup Slams in the 3D culture session on Tuesday, December 7, at 11.30 CET.
Don’t miss this opportunity!
November 15-19
We are glad to partecipate to Termis World Congress 2021. Paola Occhetta, CEO of BiomimX, is presenting “3D in vitro models for drug screening and toxicology: experiences from the EU H2020 project SINERGIA and the EURION cluster”.
October 1, 10.00 am CEST
We’re glad to communicate that Paola Occhetta, BiomimX® Srl CEO, will present “Beating organs-on-chip as technological platforms in drug screening: advanced in vitro models of human physiology and pathology” at Centro 3R third Annual Convention, on October 1 at 10.00 am.
Save the date!
September 30, 2021
We’ll be at EIC Corporate Day with Merck!
We are already excited about possible future collaborations that may arise from this experience.
BiomimX® Srl will be represented by our CEO Paola Occhetta.
September 29 – October 1, 2021
We’ll be at the next Meet in Italy for Life Sciences 2021! Our CEO, Paola Occhetta, is representing BiomimX® Srl on September 29 – October 1. Don’t miss the opportunity to know more about our innovation and technology.
September 17, 2021
Milano, 17/09/2021. Fidia Farmaceutici S.p.A. and BiomimX® Srl have signed a research collaboration agreement aimed at introducing and applying new Organs-on-Chip based technological solutions to the intra-articular medical device discovery process.
September 15, 14.30-15.30 CEST
Save the date! Upcoming webinar on Wednesday 15th September, 14.30-15.30 CEST. Within the SINERGIA2020 framework we are glad to announce that Professor Bart Spee is going to present a webinar on Liver organoids for advanced in vitro models and whole organ engineering.
June 30, 2021
Milano, 30th June 2021. Accelera – Part of NMS Group and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process.
June 10, 2021 3pm-4pm CEST
We are glad to announce that our CEO Paola Occhetta is presenting BiomimX® innovative solutions on the occasion of our win for the CrossTheBRIDGE2021.
June 16, 2021 4PM (GMT+2)
The second BiomimX Webinar is on its way, and we’re having a special guest this time! Together with Simona Marzorati, head of Laboratory at Accelera – Part of NMS Group , our COO Roberta Visone will present the potential of uHeart model throughout drug discovery and development. Don’t miss this! Register here
May 20, 2021
We are very pleased to announce that BiomimX® won first place in the 2021 Cross the Bridge competition called by Camera di Commercio Milano Monza Brianza Lodi, earning a 50.000 € prize to implement its project activities.
April 21, 2021
We are glad to announce that our CEO Paola Occhetta is participating to the Organ-on-a-Chip Symposia Series the 21st of April 2021.
She will talk about our human Osteoarthritic (OA) model uKnee and its potential as a tool for testing efficacy of anti-OA drugs and intra-articular medical devices.
Don’t miss it! Register now.
March 24, 2021 4PM (GMT+1)
Towards the replication of human complexity in vitro, we have developed uBeat® technology which allows to take the first steps to mimic human tissues behavior with an unprecedented precision.
Why not planning your next experimental campaign with something that could give you more flexibility and a better representation of clinical insights?
Learn more about uBeat® technology on our first free webinar.
Register here
February 9, 2021
We are glad to announce that our latest study “Micro-electrode channel guide (µECG) technology: an online method for continuous electrical recording in a human beating heart-on-chip” is now on-line on Biofabrication.
In this paper we present a new device capable of monitoring the electrical activity of beating cardiac microtissues, together with a proof-of-concept pharmacological validation.
This work is the result of a great collaboration between Academia (Politecnico di Milano) and Industries (BiomimX® Srl & Accelera Srl).
Read it here
January 21, 2021 (8 PM CET)
2020 has taught us how crucial is to invest in Research, mostly to reduce technical time for testing drugs and medical devices.
Paola Occhetta, BiomimX CEO, and Marco Rasponi, BiomimX President, will explain how our startup contributes to bring pharmaceutical companies to the market with more efficient therapies in a shorter time, thanks to our innovative technologies.
Don’t miss the episode of STARTUPPER broadcast on Thursday 21st January starting at 8 PM CET on channel 821 Sky.
January 20, 2021 (2.30-3.30 PM CET)
Upcoming webinar! Within the SINERGIA framework we are glad to announce that professor Paul Bourgine will be the first speaker of our webinars series, invited by BiomimX® Srl. Prof. Bourgine’s laboratory targets the development of miniaturized human bone organs (hOssicles) in mice to be used as advanced model of healthy and malignant human hematopoiesis. This talk will first cover how embryonic processes can be harnessed for the engineering of hOssicles. The advantages of the hOssicle approach as opposed to standard in vitro and in vivo models will be discussed.
Take a look!
2020
December 7th-10th , 2020
BiomimX® will partecipate to the Digital Biofit 2020 from December 7th to December 10th 2020. We are looking forward to virtually meet you during the one-to-one partnering event and to take part to this exiting Life Science fair!
Take a look!
August, 2020
The Results in Brief Article of the uHeart Project, a collaborative effort of BiomimX® and CORDIS, has been published on the CORDIS website in six different languages.
Take a look!
July 29th, 2020
We are glad to announce that today our company name, BiomimX®, and our technology name, uBeat®, have both received the trademark registration.
July, 2020
Check the newly elected Members of the European Organ-on-Chip Society (EUROoCS) Executive Board. Congratulation Marco Rasponi!
July, 2020
BiomimX® S.r.l. will participate to the online European Organ-on-Chip Society (EUROoCs) annual meeting 2020 on 8 and 9 July 2020
May, 2020
BiomimX® S.r.l. and NeuroZone S.r.l. signed a strategic commercial partnership for uKnee services
April, 2020
Stefano Piazza, Roberta Visone from BiomimX S.r.l., Simona Marzorati from Accelera and Erika Ferrari from Politecnico di Milano joined the #EUvsVIRUS hackaton, conceiving tha “BeatingCovidOnChip”, an innovative microfluidic platform to speed up the drug screening process for Covid-19 treatments.
#BeatMyCovid to #BeatThemAll!
March, 2020
Our CEO Paola Occhetta at the microphone of #Radio24 to discuss about the future goals of BiomimX®
Thanks Maurizio Melis and #SmartCity for the opportunity!
March, 2020
BiomimX® Srl is one of the 5 Top Lab-On-A-Chip Startups impacting Engineering according to StartUs Insights!
February, 2020
BiomimX® Srl winner of the prize #DigitalForHealth. Thanks to Consorzio DAFNE for the opportunity!
2019
October, 2019
BiomimX® obtains the SME Instrument phase 1
Thanks to the SME Instrument Phase 1awarded for the project uHeart, BiomimX® will accelerate its way to the market!
October, 2019
BiomimX® will partecipate to the EUSAAT Congress, the 22nd European Congress on Alternatives to Animal Testing organized in Linz
September, 2019
Best poster award at the Safety Pharmacology Society 2019 Annual Meeting
In a collaborative project of BiomimX®, Politecnico di Milano and Accelera S.r.l., Roberta Visone was awarded the first place in the 2019 Jr. Investigator Poster Contest at the Safety Pharmacology Society 2019 Annual Meeting. September 23-26, 2019, Barcelona, Spain.
Visone R, Marzorati S, Perego V, Occhetta P, Pesenti E,Rasponi M. “uHeart: a beating heart-on-chip platform for on-line recording of functional 3D cardiac microtissues’ electrical activity”
Contratulations Roberta!
June, 2019
SINERGIA project (MSCA-ITN-ETN-2019) was financed by EU Commission
BiomimX® is part of the SINERGIA network. SINERGIA aims to provide breakthrough strategies for the implementation of new in vitro preclinical platforms in terms of innovative technologies, biological models and drug screening approaches in the effort of bridging the gap between current, simplistic in vitro cultures and faithful and effective future physiological models. More info here!
June, 2019
BiomimX® receives its third Seal of Excellence H2020 from the European Commission!
2018
November, 2018
BiomimX® won the 3rd prize at the “EIT Joint Grand Final” in Budapest
On 16th November 201, BiomimX® was awarded the third prize in the competition HeadStart Funding, which was created to accelerate products and solutions in SMEs and bring the companies to an investment-ready stage.
November, 2018
BiomimX® receives a new Seal of Excellence H2020 from the European Commission
September, 2018
BiomimX® was awarded the First Prize at the Business Plan Competition at TERMIS 2018!
BiomimX® was awarded the First Prize in the Business Plan Competition in Kyoto, during the 5th World Congress of the Tissue Engineering and Regenerative Medicine International Society (Kyoto, Japan).
June, 2018
BiomimX® in Naples for the European Health Catapult and Headstart regional selection event
BiomimX® participated to the final selection, and it was voted as one of the best 8 Teams in the Headstart program. Besides being awarded a prize money (€35,000), our Team will have the possibility to mature its business plan, negotiation and pitching skills as well as to learn from experts thanks to EIT.
April, 2018
BiomimX® at Lab on a chip Symposium in Basel
BiomimX® will participate to the Lab on a chip Symposium – from molecular assays to organs on a chip organized in Basel by The Royal Society of Chemistry journal Lab on a Chip and ETH Zurich.
April, 2018
BiomimX® receives its first Seal of Excellence H2020 from the European Commission
March, 2018
BiomimX® at Bootcamp of BioInItaly/StartUp Initiative 2018 by Intesa Sanpaolo
BiomimX® has been selected and invited to the training and selection phase of the BioInItaly/StartUp Initiative 2018, in the Biotech track. Intesa Sanpaolo Start-Up Initiative is a comprehensive program aimed at technology start-ups looking for concrete business opportunities: every few months, a rigorous selection and training process leads the best start-ups to high-profile, technology-specific events called Arena Meetings, where they can pitch to international investors and corporations.
2017
November, 2017
SNSF/Innosuisse BRIDGE PoC grant for Knee-on-chip
Paola Occhetta was awarded the SNSF/CIT BRIDGE Proof-of-Concept grant for developing a Knee-on-chip platform to speed up the research for anti-osteoarthritic drugs. She will receive 130,000 Swiss francs in funding to implement her project within a collaboration between University Hospital of Basel and BiomimX®.
November, 2017
BiomimX® at Bioindustry Park thanks to Premio Marzotto
BiomimX® has classified among the 10 finalists of Premio Marzotto 2017 – Dall’idea all’impresa with its uKnee model. With its idea, BiomimX® was awarded with one year of mentoring and incubation at Bioindustry Park, a startup incubator located in Ivrea (Italy). Bioindustry Park, lead by Silvano Fumero, is the ideal location and solution to companies in need of efficiency, quality and image.
May, 2017
BiomimX® was founded after winning StartCup Lombardia 2016, in the category of Life Science & Agrofood with its uBeat® technology.
2016
April, 2016
BiomimX® among 10 finalists of Bioupper 2015
BiomimX® has classified among the 10 finalists of the first edition of Bioupper – Let’s give life to life Startups, the empowerment acceleration program for LifeTech startups organized by Novartis and Fondazione Cariplo.